Amgen Inc. stock (US0311621009): focus on Horizon integration and latest quarterly results

Biotech group Amgen has reported fresh quarterly figures and continues integrating the Horizon Therapeutics acquisition, while its stock reacts on Nasdaq. What the latest numbers and pipeline developments mean for investors watching the US pharmaceutical sector.

Biopharma group Amgen Inc. is back in the spotlight after publishing new quarterly figures and updating investors on the integration of Horizon Therapeutics, a large acquisition completed in late 2023. The latest numbers and comments from management shed light on how the US biotech heavyweight is positioning itself in a competitive market, according to Amgen investor materials as of 05/2026 and recent coverage by Reuters as of 05/2026.

In early May 2026, Amgen reported results for the first quarter of 2026, highlighting revenue trends, earnings dynamics and contributions from its expanded portfolio. The company also addressed cost structures and synergies linked to the Horizon transaction, while the Amgen stock reacted on Nasdaq, according to Amgen quarterly earnings materials as of 05/2026 and Nasdaq market data as of 05/2026.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology / pharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: US, Europe and other international pharmaceutical markets
• Key revenue drivers: Biologic therapies for oncology, inflammation and other serious diseases
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: US dollar (USD)

Amgen Inc.: core business model

Amgen Inc. is one of the largest independent biotechnology companies globally, focusing on the discovery, development and commercialization of human therapeutics. The group’s products address serious diseases such as cancer, inflammatory conditions, bone disorders and cardiovascular risks, according to Amgen company information as of 03/2026. Its strategy is built around biologics and targeted therapies derived from advanced science.

The company operates a fully integrated model that combines research and development, manufacturing, regulatory expertise and global commercial capabilities. This allows Amgen to control key steps from early-stage discovery through large-scale production of biologic medicines, which can be complex and capital-intensive. The group’s manufacturing network includes facilities in the United States and other regions, enabling supply to major markets, according to Amgen locations overview as of 02/2026.

On the commercial side, Amgen markets a portfolio of established blockbuster medicines alongside newer launches and biosimilars. Established brands in oncology, nephrology and bone health still play a significant role, but the company has been working to offset pricing pressure and biosimilar competition by expanding into new therapeutic areas. The acquisition of Horizon Therapeutics broadened its presence in immunology and rare diseases, reflecting a push into specialty indications with high unmet medical need, as outlined in Amgen transaction communications as of 10/2023.

Amgen’s business model also depends heavily on intellectual property and regulatory exclusivity for its innovative medicines. As key patents expire, the company faces competition from biosimilars, including in the US. To navigate this, Amgen invests in next-generation products and life-cycle management for existing therapies, while also developing its own biosimilar portfolio. This dual strategy aims to retain value in mature categories while competing in the growing biosimilars market, according to Amgen strategic presentations as of 2025.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue base is diversified across several key biologic therapies, although the mix continues to evolve over time. Legacy products in oncology and supportive care still contribute meaningfully, but growth increasingly comes from newer launches and recently acquired medicines. Management has highlighted oncology, inflammation and rare disease assets as central pillars of its strategy, according to Amgen investor presentations as of 2025.

In recent quarterly updates, the company pointed to volume growth in certain newer products, partly offsetting price erosion and competition in mature brands. Contributions from the Horizon Therapeutics portfolio have become a more visible component of total revenue, with management emphasizing integration benefits and potential cross-selling opportunities in key geographies, according to Amgen earnings releases as of 05/2026.

Beyond individual drugs, Amgen’s biosimilars portfolio is an additional growth lever. The company is active in developing biosimilar versions of blockbuster biologics originally developed by other manufacturers, allowing it to participate in segments that are transitioning to more price-sensitive competition. While biosimilars generally offer lower margins than innovative products, they can still add scale to revenue and help offset headwinds elsewhere in the portfolio, as discussed in Amgen biosimilars information as of 2025.

Geographically, the United States remains the largest revenue contributor for Amgen, with Europe and other international markets providing additional diversification. Pricing dynamics and reimbursement frameworks vary by region, so product performance can differ significantly between the US and ex-US markets. For US-focused investors, Medicaid, Medicare and commercial payer policies all influence unit volumes and net pricing, especially for high-cost biologics, according to analyses referenced in Reuters coverage as of 02/2025.

Industry trends and competitive position

Amgen operates in a highly competitive global biopharmaceutical industry characterized by intense R&D spending, rigorous regulatory oversight and significant patent cliffs. Large pharmaceutical peers, other biotech players and emerging innovators all compete for market share in target indications. To defend and grow its position, Amgen invests heavily in clinical development, real-world evidence and manufacturing technologies, according to Amgen annual reports as of 02/2025.

One important industry trend is the shift toward specialty medicines and targeted therapies, which typically command higher prices but also face scrutiny from payers and regulators. Amgen’s focus on serious diseases and biologics positions it within this trend, but also exposes the company to policy initiatives aimed at reducing drug costs, especially in the United States. Discussions around Medicare negotiation and pricing transparency can influence sector valuations and uncertainty levels for investors, as noted in sector-focused commentary by Bloomberg as of 2025.

Another structural dynamic is the maturation of the biosimilars market. Amgen faces biosimilar pressure on some of its established products, but the company also participates as a biosimilar supplier, giving it exposure to both sides of this shift. Successful execution in biosimilars requires scale in manufacturing, strong regulatory dossiers and robust commercial capabilities. Amgen’s long experience with biologic production is a potential advantage, but competition from other global players remains intense, according to industry data referenced by Evaluate Pharma as of 2025.

From a competitive standpoint, Amgen’s acquisition of Horizon Therapeutics was a strategic move intended to strengthen its portfolio in immunology and rare diseases, areas where long-duration revenue and lower competitive intensity can sometimes be found. However, absorbing a large transaction also brings integration risk, execution complexity and potential scrutiny from regulators. The company has communicated synergy expectations and integration milestones to the market, which investors will be monitoring in upcoming earnings cycles, according to Amgen transaction updates as of 2024.

Why Amgen Inc. matters for US investors

For US investors, Amgen represents exposure to a large-cap biotech name with a diversified portfolio and a significant presence in the domestic healthcare system. The stock trades on Nasdaq, where it is part of major indices that are widely followed by institutional and retail investors. As such, Amgen can influence biotech sector sentiment and is often included in healthcare-focused exchange-traded funds, according to index composition data cited by S&P Dow Jones Indices as of 2025.

Amgen’s financial results are closely watched as a gauge of pricing trends, payer behavior and pipeline productivity in the US biopharmaceutical market. Because many of its therapies are reimbursed under Medicare, Medicaid and commercial plans, changes in US health policy can directly affect revenue and margins. Earnings releases, guidance updates and management commentary therefore carry informational value that can extend beyond the company itself and inform investor views on the broader healthcare space, as seen in coverage by CNBC as of 2025.

Additionally, Amgen’s dividend policy and share repurchase activities have made the stock relevant for income-oriented US investors seeking exposure to healthcare. While any future capital allocation decisions will depend on cash flows, R&D needs and regulatory developments, the company’s past record of returning capital to shareholders is a data point that many market participants consider when assessing stability and risk. However, as always, distributions are not guaranteed and can be adjusted based on business conditions, as stated in prior financial filings in Amgen SEC filings as of 02/2025.

Conclusion

Amgen Inc. remains a central name in the US biotech landscape, combining an established commercial portfolio with a pipeline and acquisition-driven expansion strategy. The latest quarterly figures and Horizon integration updates provide investors with fresh data points on revenue mix, cost evolution and execution. At the same time, the company continues to operate in a competitive, highly regulated industry where patent expirations, pricing reforms and clinical outcomes can all move sentiment. For observers of the healthcare sector, Amgen’s progress over coming quarters will likely serve as a key reference for how large-cap biotech groups navigate innovation pressures and policy shifts in the United States and abroad.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.